{"schema_version":"secwatch.filing_event.v1","accession":"0000899923-26-000012","form_type":"8-K","ticker":"MYGN","cik":"0000899923","company_name":"MYRIAD GENETICS INC","filed_at":"2026-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.995248+00:00","generated_at":"2026-05-16T01:20:24.161003+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Myriad Genetics Q4 2025 revenue $209.8M, net loss $7.9M; reiterates 2026 guidance","bullets":["GAAP net loss $7.9M ($0.08 loss per share); adjusted EPS $0.04.","Revenue $209.8M roughly flat YoY; hereditary cancer testing volume +9%, GeneSight +9%, prenatal -6%.","Full-year 2025 revenue $824.5M down 2%; reiterates 2026 revenue guidance $860-880M.","Adjusted EBITDA $14.3M in Q4; company expects 2026 adjusted EBITDA $37-49M.","Plans to launch Precise MRD in March 2026, AI-enabled Prolaris in Q2 2026, FirstGene in H2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0000899923-26-000012","json":"https://secwatch.observer/filing/0000899923-26-000012.json","markdown":"https://secwatch.observer/filing/0000899923-26-000012.md","text":"https://secwatch.observer/filing/0000899923-26-000012.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/899923/000089992326000012/0000899923-26-000012-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/899923/000089992326000012/mygn-20260223.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T01:20:24.161003+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}